Diabetes Diminishes the Portal-Systemic Collateral Vascular Response to Vasopressin via Vasopressin Receptor and G\alpha Proteins Regulations in Cirrhotic Rats

Jing-Yi Lee1, Teh-Ia Huo1,4, Sun-Sang Wang2,5, Hui-Chun Huang2,4*, Fa-Yauh Lee2,4*, Han-Chieh Lin2,4, Chiao-Lin Chuang2,3, Shou-Dong Lee2,6

1 Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, 2 Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, 3 Divisions of General Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4 Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 5 Department of Medical Affairs and Planning, Taipei Veterans General Hospital, Taipei, Taiwan, 6 Division of Gastroenterology, Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan

Abstract

Liver cirrhosis may lead to portal-systemic collateral formation and bleeding. The hemostatic effect is influenced by the response of collateral vessels to vasoconstrictors. Diabetes and glucose also influence vasoresponsiveness, but their net effect on collaterals remains unexplored. This study investigated the impact of diabetes or glucose application on portal-systemic collateral vasoresponsiveness to arginine vasopressin (AVP) in cirrhosis. Spraque-Dawley rats with bile duct ligation (BDL)-induced cirrhosis received vehicle (citrate buffer) or streptozotocin (diabetic, BDL/STZ). The in situ collateral perfusion was done after hemodynamic measurements: Both were perfused with Krebs solution, D-glucose, or D-glucose and NaF, with additional OPC-31260 for the BDL/STZ group. Splenorenal shunt vasopressin receptors and G\alpha proteins mRNA expressions were evaluated. The survival rate of cirrhotic rats was decreased by STZ injection. The collateral perfusion pressure changes to AVP were lower in STZ-injected groups, which were reversed by OPC-31260 (a V2R antagonist) and overcome by NaF (a G protein activator). The splenorenal shunt V2R mRNA expression was increased while G\alpha proteins mRNA expressions were decreased in BDL/STZ rats compared to BDL rats. The G\alpha2 and G\alpha11 mRNA expressions also correlated with the maximal perfusion pressure changes to AVP. Diabetes diminished the portal-systemic collateral vascular response to AVP in rats with BDL-induced cirrhosis, probably via V2 receptor up-regulation and G\alpha proteins down-regulation.

Introduction

Liver cirrhosis is characterized by increased intrahepatic resistance and splanchnic hyperemia with elevated portal pressure, the so-called portal hypertension [1]. As portal pressure increases, portal-systemic collaterals develop to divert portal blood flow to the systemic circulation, among which gastroesophageal varices are the most prominent [2]. Vascular endothelial growth factor, a vascular endothelium-derived factor mediating vasodilation and angiogenesis, also participates in the development of portal hypertension and varices [3,4]. Variceal hemorrhage is the most dreadful and challenging complication [5]. The current treatment strategy aims to reduce portal inflow, portal pressure and/or constrict collateral vasculature. Therefore, factors that alter collateral vascular contractility may contribute to the control of variceal hemorrhage.

Arginine vasopressin (AVP) and its long-acting analogue terlipressin have been used to control variceal bleeding and hepatorenal syndrome [6]. Recently, AVP has been shown to directly constrict portal-systemic collaterals of portal hypertensive and bile duct-ligated (BDL) cirrhotic rats [7,8]. The vascular effects of AVP begin with its binding to G-protein-coupled V1a receptor. Subsequently, the activation of G-protein \( \alpha \)-subunits like G\alpha11 recruits protein kinase C and phospholipase C. They release Ca\(^{2+} \) from intracellular stores and induce vasoconstriction [9].

The liver regulates blood glucose levels by gluconeogenesis and glycogenolysis, which are essential in carbohydrate metabolism. In cirrhosis, impaired insulin-mediated glucose uptake contributes to profound and sustained hyperglycemia [10]. Previous analysis showed that up to 96% of cirrhotic patients were glucose intolerant and 30% might develop clinical diabetes [11,12]. Long-standing diabetes may lead to structural and functional vascular anomalies [13]. Hyperglycemia may cause divergent vascular actions in different situations. In previous investigations, hyperglycemia impaired the endothelium-dependent relaxation of rat isolated mesenteric resistance arteries [14] and acetylcholine-induced vasodilation of renal arterioles [15]. *In vivo* studies

Citation: Lee J-Y, Huo T-I, Wang S-S, Huang H-C, Lee F-Y, et al. (2013) Diabetes Diminishes the Portal-Systemic Collateral Vascular Response to Vasopressin via Vasopressin Receptor and G\alpha Proteins Regulations in Cirrhotic Rats. PLoS ONE 8(7): e67703. doi:10.1371/journal.pone.0067703
indicated that hyperglycemia also significantly suppressed endothelium-mediated vasodilation of rats with streptozotocin (STZ)-induced diabetes [16]. On the other hand, abolished Ca^{2+} transients in response to physiological agonists have been reported in vascular smooth muscle cells of diabetic animals [17]. In diabetic rats, aortic smooth muscle and portal vein contractile response to vasoactivators were abolished [18]. In addition, renal perfusion pressure responses to AVP were markedly blunted in diabetic rats [19].

Hyperglycemia and glucose application alter vascular reactivity in different vascular beds, but the corresponding influences on the portal-systemic collateral vascular bed of cirrhosis have not yet been surveyed. We hypothesized that diabetes and/or glucose application may elicit changes of collateral vasoresponsiveness to AVP in cirrhotic rats. Furthermore, the results may provide the information capable of improving the treatment efficacy of vasoconstrictors in cirrhotic and diabetic patients with variceal hemorrhage.

Materials and Methods

Animal model: common bile-duct ligation (BDL)

Male Sprague-Dawley rats (240–270 g) received BDL to induce liver cirrhosis [20]. Under ketamine anesthesia (100 mg/kg, intramuscularly), the common bile duct was exposed and catheterized by a PE-10 catheter, followed by 3–0 silk ligation. Then 10% formalin (~100 μl/100 g body weight) was slowly injected into the biliary tree to prevent the subsequent dilatation of the ligated residual bile duct. The common bile duct was cut between the ligatures after the PE-10 catheter was removed and the ligatures were tightened. Secondary biliary cirrhosis was noted since five weeks after ligation. To avoid coagulation defects, BDL rats were given vitamin K injection (50 μg/kg intramuscularly) weekly.

This study was approved by Taipei Veterans General Hospital Animal Committee [IUACU no. 99–123] and was conducted according to the principles of laboratory animal care [Guide for the Care and Use of Laboratory Animals (1985), DHEW Publication no. (NIH) 85–23: Office of Science and Health Reports, DRR/NIH, Bethesda, MD, U.S.A.].

Experimental model of diabetes

Diabetes was induced by intraperitoneal injection of STZ (60 mg/kg in citrate buffer) 2 weeks after BDL as previously described [21]. Blood samples were withdrawn from tail veins and blood glucose levels were assessed before hemodynamic measurement. Rats with blood glucose levels higher than 200 mg/dl were considered diabetic and eligible for the experiments. Rats with blood glucose levels between 100 and 200 mg/dl received an oral glucose tolerance test (OGTT): Blood glucose levels were measured 120 min after the D-glucose load (2 g/Kg). Rats with glucose levels higher than 200 mg/dl after OGTT were also considered diabetic.

Systemic and portal hemodynamic measurements

The right femoral artery of BDL rats was cannulated with a PE-50 catheter connected to a Spectramed DTX transducer (Spectramed Inc., Oxnard, CA, USA). The abdomen was then opened with a mid-line incision and the mesenteric vein was cannulated with an 18-gauge Teflon cannula connected to a Spectramed DTX transducer. Continuous recordings of mean arterial pressure (MAP), heart rate (HR) and portal pressure (PP) were performed on a multi-channel recorder (model RS 3400, Gould Inc., Cupertino, CA, USA). The external zero reference was at the level of the right atrium.

In situ perfusion of portal-systemic collaterals

The in situ perfusion system was performed as previously described [7,8]. Both jugular veins were cannulated with 16-gauge Teflon cannulas to ensure an adequate outflow without any resistance. Heparin (200 u/100 g) was injected through one of the cannulas. The 18-gauge Teflon cannula inserted into the distal mesenteric vein served as the perfuse inlet. To exclude the liver from perfusion, the second loose ligature around the portal vein was tightened. The animal was then transferred into a warm chamber (37±0.5°C). An open circuit perfusion was then started.

Figure 1. Study design.

do:10.1371/journal.pone.0067703.g001
with Krebs solution (composition in mM: NaCl, 118; KCl, 4.7; KH₂PO₄, 1.2; MgSO₄, 1.2; CaCl₂, 2.5; NaHCO₃, 25; dextrose 11.0; pH 7.4, 37°C) containing 3% wt/vol albumin (factor V bovine serum albumin, Sigma, St. Louis, MO, USA) by a roller pump (model 505S, Watson-Marlow Limited, Falmouth, Cornwall, UK). The perfusate was equilibrated and oxygenated with carbogen gas (95% O₂-5% CO₂) by a silastic membrane lung. Pneumothorax was created by opening slits through the diaphragm to increase resistance in pulmonary arteries and prevent the perfusate from entering the left heart chambers. A

| Table 1. Primers of target and housekeeping genes used for RT-PCR. |
|---|
| **Names** | **Sense** | **Antisense** | **NCBI accession number** |
| V₁aR | F-5'-CGCACTGTGAAGATGACCTTT-3' | R-5'-TGGAAAGGTTTCTGATCG-3' | NM053019.2 |
| V₂R | F-5'-ACCCCTCTCTCTGTGCAG-3' | R-5'-AGGACATGAGCAACACAAA-3' | NM019136.1 |
| Gasq | F-5'-GCACAATGGTCGAGGCT-3' | R-5'-GATAGGAAGGTCAGCACACA-3' | NM031036 |
| Gα₁₁ | F-5'-CCTGACACCTGGAAACCACAT-3' | R-5'-TCACTAGCAGAGTCATCTGAAAC-3' | NM031033 |
| Gas | F-5'-GCCTGAAAACATGTCCACTCC-3' | R-5'-TGCAAGTCAACATGAGAGGC-3' | NM021845 |
| Gαi | F-5'-TACAGGACACCATCCAGTC-3' | R-5'-AAGTGGGTTCTCGAGCC-3' | NM017327 |
| β-actin | F-5'-CGCCCTAGGCACACAGGTTG-3' | R-5'-GCTGGGTTGTGAAGGTCAAAA-3' | |

doi:10.1371/journal.pone.0067703.t001

**Figure 2. Concentration-response curves to AVP in portal-systemic collateral vascular beds.** (A) Concentration-response curves of BDL and BDL/STZ rats. BDL: vehicle injection; BDL/STZ: STZ injection; K: Krebs solution; G: D-glucose, expressed as absolute increase over baseline value. Concentration-response curves of the BDL/STZ/K group were significantly weaker than that of the BDL/K and BDL/G groups (mean±SDM). (B) Concentration-response curves of BDL/STZ rats. K: Krebs solution; G: D-glucose; OPC-31260: OPC-31260, expressed as absolute increase over baseline value. Concentration-response curves of the BDL/STZ/OPC-31260 group were significantly higher in 10⁻¹⁷ M AVP than that of the BDL/STZ/K and BDL/STZ/G groups.

doi:10.1371/journal.pone.0067703.g002
Spectramed DTX transducer attached to the Gould model RS 3400 recorder was connected to continuously monitor and record continuously the pressure in the portal-systemic collateral vascular bed. All the experiments were performed 25 min after starting perfusion at a constant rate of 12 nl/min. In each individual preparation, the contracting capability of the portal-systemic collaterals was challenged with a 125-mM potassium chloride solution at the end of the experiments.

Ribonucleic acid isolation and real-time PCR analysis

Splenoportal shunt, the most prominent intra-abdominal portal-systemic collateral was dissected and immediately stored in liquid nitrogen after the \textit{in situ} perfusion experiments. Total RNA was extracted using the SV Total RNA Isolation System (Promega, USA). Total RNA (1 µg) was reverse-transcribed to cDNA with ImProm-II Reverse Transcriptase (Promega, Wisconsin, USA). Quantitative RT-PCR was performed by a LightCycler (LightCycler 480, Roche Diagnostics, Mannheim, Germany) and a standard LightCycler amplification cycle protocol was established.

The amplification cycle began with a denaturation program for 10 min at 95°C. cDNA was then amplified by 40 cycles of the time profiles as: 15 s at 95°C (denaturation), 30 s at 58°C for vasopressin receptors (V_1aR, V_2R), G proteins (G_{q11}, G_{q10}, G_{q6}), and β-actin (annealing), and 10 s at 72°C (elongation). The melting curve program was performed for 0 s at 95°C, 15 s at 57°C and a linear temperature transition at 0.05°C·s^{-1} from 57°C to 95°C with continuous fluorescence acquisition. The final segment consisted of a cooling program to 40°C. The products were standardized with a housekeeping gene, β-actin, from the same RNA samples. Quantitative analysis was measured with LightCycler analysis software (Roche Diagnostics, Mannheim, Germany). Primer sequences of the target and housekeeping genes are listed in Table 1.

**Experimental design (Figure 1)**

Two weeks after BDL, 98 rats were randomly allocated to receive intraperitoneal injection of vehicle (cirrhotic control, BDL, n = 31) or STZ 60 mg/kg (cirrhotic and diabetic, BDL/STZ, n = 67). On the 43rd day after BDL, the MAP, PP and HR were measured. Collateral vascular responsiveness to AVP (10^{-10}–10^{-7} M) was evaluated with the following perfusions: BDL: groups were perfused with (1) Krebs solution (BDL/K), (2) 45 mM D-glucose (BDL/G), (3) 45 mM D-glucose and 10 mM sodium fluoride (NaF, a G protein activator; BDL/G+NaF); BDL/STZ groups were perfused with (4) Krebs solution (BDL/STZ/K), (5) 45 mM D-glucose (BDL/STZ/G), (6) 45 mM D-glucose and 10 mM NaF (BDL/STZ/G+NaF), or (7) 1 µM OPC-31260 (a selective V_2 receptor antagonist; BDL/STZ/OPC-31260). After the perfusion experiments, the splenoportal shunts of BDL and BDL/STZ rats perfused with Krebs solution were isolated and dissected for real-time PCR analysis.

**Drugs**

AVP, streptozotocin, NaF, OPC-31260 and the reagents for preparing Krebs solution were purchased from Sigma (Sigma Chemical Co., St. Louis, MO, USA). All of the solutions were freshly prepared on the days of the experiments.

**Data Analysis**

The results were expressed as mean±SDM. Changes in perfusion pressure (mmHg) from baseline were calculated for each concentration in each rat. Statistical analyses were performed using the independent Student’s \textit{t}-test or one-way ANOVA followed by Bonferroni post-hoc test as appropriate. The survival rates of the control and diabetic groups were analyzed by log-rank test (Mantel-Cox). The concentration of vasopressin exhibiting 50% of the maximal response (EC50) in each preparation was calculated from the sigmoid logistic curves and expressed as nM.

**Table 2.** Body weight, serum glucose concentration and hemodynamics in BDL rats with saline or STZ injection.

| Group   | n | BW (g)       | glucose (mg dl^{-1}) | MAP (mmHg) | PP (mmHg) | HR (beats min^{-1}) |
|---------|---|--------------|-----------------------|------------|-----------|---------------------|
| BDL     | 26| 341±44       | 99.5±28.0             | 96.8±12.4  | 17.2±3.2  | 299±52              |
| BDL/STZ | 30| 285±53†      | 390.3±109.4†          | 87.1±16.8* | 16.6±2.6  | 263±48*             |

BW: body weight; MAP: mean arterial pressure; PP: portal pressure; HR: heart rate; BDL: bile duct ligation; STZ: streptozotocin.

*: P<0.05 vs. BDL rat; †: P<0.01 vs. BDL rat.

doi:10.1371/journal.pone.0067703.t002

**Table 3.** Maximum increase of perfusion pressure and EC50 in BDL rats with STZ injection.

| Group   | n | Maximum increase (mmHg) | EC50 (nM) |
|---------|---|--------------------------|-----------|
| BDL/G+NaF | 7 | 19.71±2.98               | 2.023±0.370 |
| BDL/STZ/K | 7 | 9.14±3.39†              | 3.005±0.336† |
| BDL/STZ/G | 9 | 9.67±2.65†              | 2.973±0.336† |
| BDL/STZ/G+NaF | 6 | 17.5±4.55               | 1.975±0.458 |

*: P<0.01 vs. BDL/STZ/G+NaF rat; †*: P<0.01 vs. BDL/G+NaF rat.

doi:10.1371/journal.pone.0067703.t003

**Figure 3.** Correlations between maximal increases of perfusion pressure and the blood glucose concentrations in vehicle- and STZ-injected BDL rats with Krebs solution perfusion. The maximal perfusion pressure changes to AVP were negatively correlated with their blood glucose concentrations in the BDL/K and BDL/STZ/K groups (P = 0.0324, r = 0.5199).

doi:10.1371/journal.pone.0067703.g003

**Table 2.** Body weight, serum glucose concentration and hemodynamics in BDL rats with saline or STZ injection.
The results were considered statistically significant at a two-tailed P value less than 0.05. Simple linear regression was applied to analyze the correlation of splenorenal shunt Gq protein mRNA expressions and the maximal perfusion pressure changes to AVP.

Results

Survival rates of vehicle- (cirrhotic group, BDL) and STZ-injected (cirrhotic and diabetic group, BDL/STZ) BDL rats

On the 43rd day after BDL, the survival rates of BDL and BDL/STZ groups were analyzed by log-rank test. The survival rate of the BDL group (87.1%) was significantly higher than that of the BDL/STZ group (49.3%, P = 0.0003).

Baseline glucose and hemodynamic data

Only BDL/STZ rats with blood glucose levels in excess of 200 mg/dl were considered diabetic. The blood glucose level of vehicle-injected BDL rats was below 100 mg/dl. Compared to the BDL group, the BDL/STZ group had significantly lower baseline body weight (BW), MAP and HR (Table 2). There were no significant differences in glucose, BW, MAP, PP, and HR between BDL rats perfused with Krebs solution (BDL/K, n = 10), 45 mM D-glucose (BDL/G, n = 9), or 45 mM D-glucose and NaF (BDL/G + NaF, n = 7). The parameters were also similar among BDL/STZ rats perfused with Krebs solution (BDL/STZ/K, n = 7), 45 mM D-glucose (BDL/STZ/G, n = 9), 45 mM D-glucose and NaF (BDL/STZ/G + NaF, n = 6), or OPC-31260 (BDL/STZ/OPC-31260, n = 8) (P > 0.05).

Concentration-response relationships to AVP

a. Vehicle- vs. STZ-injected BDL rats with Krebs solution or D-glucose perfusion. Figure 2A depicts the comparison between BDL and BDL/STZ rats perfused with Krebs solution or D-glucose (BDL/K, BDL/G, BDL/STZ/K and BDL/STZ/G). Compared to the BDL group, the perfusion pressure changes to AVP were significantly alleviated in BDL/STZ group (P = 0.033). There was no significant difference between the BDL/K and BDL/G or the BDL/STZ/K and BDL/STZ/G groups.

b. STZ-injected BDL rats with Krebs solution, D-glucose, or OPC-31260 perfusion. Figure 2B reveals the concentration-response curves of BDL/STZ rats perfused with Krebs solution, D-glucose, or OPC-31260 (BDL/STZ/K, BDL/STZ/G, and BDL/STZ/OPC-31260). The perfusion pressure change of the BDL/STZ/OPC-31260 group was significantly higher than that of the BDL/STZ/K (10 µM: 11.38 ± 3.64 vs. 6.71 ± 2.43, P = 0.004) and BDL/STZ/G (10 µM: 11.38 ± 3.64 vs. 7.44 ± 2.38, P = 0.009) groups.

c. Maximum increases of perfusion pressure correlated with the blood glucose concentrations of vehicle- and STZ-injected BDL rats. Figure 3 demonstrated that the maximal perfusion pressure changes of the BDL/K and BDL/STZ/K groups negatively correlated with their blood glucose concentrations (P = 0.0324, r = −0.5199).

d. Maximum increase of perfusion pressure and EC50 to AVP of STZ-injected BDL rats with different pre-incubations. Table 3 shows the maximum increase of collateral perfusion pressure and EC50 to AVP of the BDL/STZ rats with Krebs solution, D-glucose, or D-glucose and NaF perfusion (BDL/STZ/K, BDL/STZ/G, BDL/STZ/G + NaF). The maximum perfusion pressure changes to AVP of the BDL/STZ/G + NaF group were significantly higher than those of the BDL/STZ/K and BDL/STZ/G groups (P < 0.001). The EC50 of BDL/STZ/G + NaF group was also significantly lower than those of the BDL/STZ/K and BDL/STZ/G groups (P < 0.001). The maximum perfusion pressure and EC50 were also evaluated in BDL rats perfused with D-glucose and NaF (BDL/G + NaF). There were no significant differences between BDL/G + NaF and BDL/STZ/G + NaF groups (P > 0.05).

e. Splenorenal shunt vasopressin receptors mRNA expressions. In figure 3, splenorenal shunt mRNA expression of V1aR was not different between BDL and BDL/STZ groups (V1aR/β-actin: 0.00167 ± 0.000348 vs. 0.00205 ± 0.00078, P > 0.05). However, the BDL/STZ group had a higher V2R mRNA expression than that of the BDL group (V2R/β-actin: 0.000037 ± 0.000020 vs. 0.000152 ± 0.000100, P = 0.023).

f. Splenorenal shunt Gq family proteins mRNA expressions and correlations with the maximal AVP responsiveness. Figure 4 reveals the splenorenal shunt mRNA expressions of Gq, G11, Gaq, and Gas proteins. Compared to the BDL group, the BDL/STZ group had significantly decreased mRNA expressions of Gq, G11, Gaq, and Gas proteins (Gq/β-actin: 0.01788 ± 0.00520 vs. 0.01102 ± 0.00312, P = 0.021; G11/β-actin: 0.01051 ± 0.00297 vs. 0.00666 ± 0.00244, P = 0.045; Gaq/β-actin: 1.174 ± 0.302 vs. 0.533 ± 0.146, P = 0.001; Gas/β-actin: 0.0606 ± 0.0122 vs. 0.0404 ± 0.0111, P = 0.020).

Simple linear regression analysis between the Gaq, G11, Gaq, and Gas mRNA expressions and the maximal perfusion pressure changes in the BDL and BDL/STZ groups showed a significant correlation of Gaq and G11 expressions with the maximal perfusion pressure changes (P = 0.002, R = 0.550 and P = 0.039, R = 0.392, respectively). However, Gaq and G11 expressions did not correlate with the maximal perfusion pressure changes (P > 0.05).

Discussion

The present study indicates that diabetes diminishes the portal-systemic collateral AVP response in cirrhotic rats, which may be related to V2 receptor up-regulation and Gaq proteins down-regulation. This is the first time that an animal model with BDL-induced cirrhosis and STZ-induced diabetes is established.

In this study, the collateral AVP vasoresponse was poorer in hyperglycemic than in normoglycemic BDL rats. Furthermore, the maximal perfusion pressure changes of hyperglycemic and normoglycemic BDL rats negatively correlated with their blood glucose concentrations. Previous studies also demonstrated that the decreased vasocontractile response in diabetic animals [22,23] and the impaired AVP response may be due to vasopressin receptors desensitization [24]. Nevertheless, regional differences and experimental settings should be considered, since AVP...
response is reduced in coronary arteries but increased in renal arteries in STZ-diabetic rats [25].

Acute glucose exposure is deleterious for endothelial cells and vasodilatory action in diabetic and normal humans [26]. Impaired vasorelaxation has also been described in diabetic rats [4]. However, out data showed that D-glucose perfusion did not modify AVP responsiveness in cirrhotic rats with or without STZ-induced diabetes. This implies that acute glucose administration poses a less prominent influence on collateral vasoresponsiveness than chronic hyperglycemia.

Vasopressins act through G protein-coupled receptors V1aR, V1bR, and V2R. V1R down-regulation alleviates AVP response in rats with diabetes is, at least partly, associated with G proteins. Together, an ameliorated collateral AVP responsiveness of cirrhotic rats with diabetes is at least partly ascribed to V1R up-regulation. Consistently, V2R mediated vasorelaxation to AVP in diabetic patients and animals [29–31].

The splenorenal shunt Gαq, Gα11, Gαs and Gα11 mRNA expressions were down-regulated in STZ-injected BDL rats. Although Gαs mediates vasorelaxation and Gαq, Gα11, Gα11 elicited vasoconstriction, Gαq down-regulation did not overcome the net effect of Gαq, Gα11 and Gαs. Furthermore, the collateral maximal pressure changes correlated with Gαq and Gα11 expressions, but not Gα11 and Gαs. Preincubation with NaF, a G protein activator in STZ-injected cirrhotic rats increased the maximal pressure changes and decreased the EC50 to AVP as compared with those without. NaF also abrogated the difference of maximal AVP response between BDL and BDL/STZ rats. Taken together, an ameliorated collateral AVP responsiveness of cirrhotic rats with diabetes is, at least partly, associated with Gαq down-regulation.

In the current study, cirrhotic rats with diabetes had significantly lower BW than those without diabetes. Decreases in BW, MAP and HR had been found in STZ-diabetic rats [32]. One concern is if the difference in BW influences vascular tone. The lower weight may be caused by dehydration related to diabetes and/or decreased adipose tissue. Adipose tissue elevates estrogen levels that cause nitric oxide (NO)-mediated vasodilatation [33,34], while dehydration stimulates vasoconstriction via release of endogenous vasopressin [35]. Accordingly, the collateral vasocontractile response could be enhanced in STZ-injected BDL rats. However, the present study demonstrates the opposite. It can be inferred that BW loss does not affect collateral vasoresponsiveness in cirrhotic rats with diabetes.

This study has some limitations. The perfusion experiments could only be performed on the survived. Therefore, the vasoresponse between survivors and non-survivors could not be compared. Furthermore, the perfusion study could not be performed on sham-operate rats since they do not develop the pathological portal-systemic collaterals. Another concern is the potential influences of different animal models on the vasoresponsiveness. BDL is a well-established technique to induce secondary biliary cirrhosis with NO over-expression and hepatopulmonary syndrome [36]. It has been applied in our previous studies addressing the vasoresponsiveness in cirrhosis [37,38]. Hepatotoxins, such as carbon tetrachloride (CCl4), have also been used to elicit cirrhosis. However, BDL could be more feasible for vascular study since CCl4 induced vascular endothelial damage in both animal and human studies [39,40], which might adversely influence the finding.

The survival rate of STZ-injected BDL rats (49.3%) was significantly lower than that of vehicle-injected BDL rats (87.1%). Consistently, the five-year cumulative survival rate of cirrhotic patients with normal glucose tolerance was 94.7%, whereas that of cirrhotic patients with diabetes was 36.6% [41]. In another study, diabetes exacerbated liver failure and increased mortality in cirrhotic patients [42]. Our data are quite reliable since the experiments have been done on animals of the same species, raised in the same highly controlled environment, and fully randomized.

In conclusion, cirrhotic rats with diabetes exert poorer portal-systemic collateral AVP response than normoglycemic cirrhotic rats. This is related to vascular V2R up-regulation and G proteins down-regulation, especially Gαq and Gα11. Acute glucose perfusion does not influence collateral AVP responsiveness, suggesting that long-term glycemic control is pivotal for improving the collateral vasocontractile response during variceal bleeding in cirrhosis. Furthermore, Gαq protein signaling pathway may be a potential therapeutic target.

Acknowledgments

The experiments were assisted in part by the Animal Center of Department of Medical Research and Education at Taipei Veterans General Hospital. The authors would also like to thank Yi-Chou Chen for his technical assistance.

Author Contributions

Conceived and designed the experiments: FYL, HCH, JYL, CLC. Performed the experiments: JYL. Analyzed the data: FYL, HCH, TIH, JYL, CLC. Contributed reagents/materials/analysis tools: FYL, SSW. Performed the experiments: JYL. Analyzed the data: FYL, HCH, TIH, JYL, CLC. Wrote the paper: FYL, HCH, TIH, JYL, CLC. Data acquisition: TY, FYL, HCH, TIH, JYL, CLC. Contributed reagents/materials/analysis tools: FYL, SSW. Manuscript revision: FYL, HCL, SSW, SDL. Contributed reagents/materials/analysis tools: FYL, SSW. Drafted the manuscript: FYL, HCH, JYL, CLC. Conceived and designed the experiments: FYL, HCH, JYL, CLC. Data analysis: FYL, HCH, TIH, JYL, CLC. Wrote the paper: FYL, HCH, TIH, JYL, CLC. Manuscript revision: FYL, HCL, SSW, SDL.
27. Trinder D, Phillips PA, Risvanis J, Hutchins AM, MacGregor D, et al. (1995) Down-regulation of vasopressin V1a receptor mRNA in diabetes mellitus in the rat. Clin Sci 88: 671–674.

28. Phillips PA, Risvanis J, Hutchins AM, Burrell LM, MacGregor D, et al. (1995) Down-regulation of vasopressin V1a receptor mRNA in diabetes mellitus in the rat. Clin Sci 88: 671–674.

29. Medina P, Segarra G, Vila JM, Chua P, Domenech C, et al. (1999) V2-receptor-mediated relaxation of human renal arteries in response to desmopres- sin. Am J Hypertens 12: 188–193.

30. Tamaki T, Kiyomoto K, He H, Tomohiro A, Nishiyama A, et al. (1996) Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles. Kidney Int 49: 722–729.

31. Tagawa T, Inaiizumi T, Shiramoto M, Endo T, Hironaga K, et al. (1995) V2 receptor-mediated vasodilation in healthy humans. J Cardiovasc Pharmacol 25: 387–392.

32. Raimondi L, De Paoli P, Mannucci E, Leonardo G, Saritani L, et al. (2004) Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 53: 1927–1933.

33. Nelson LR, Buhm SE (2001) Estrogen production and action. J Am Acad Dermatol 45: S116–S124.

34. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN (2002) Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyproges- terone acetate or progesterone. Stroke 33: 1685–1691.

35. Heinemann A, Schuligo RL, Hippe IT, Stauber RE (2009) Sorafeln treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. Clin Sci (Lond) 124: 457–466.

36. Chang CC, Chuang CL, Lee FY, Wang SS, Lin HC, et al. (2013) Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. Clin Sci (Lond) 124: 457–466.

37. Huang HC, Chang CC, Wang SS, Lee FY, Teng TH, et al. (2012) The roles of angiotensin ? receptors in the portal-systemic collaterals of portal hypertensive and cirrhotic rats. J Vasc Res 49: 160–168.

38. Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, et al. (2004) Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats. Eur J Clin Invest 34: 290–296.

39. Holiinger MA (1982) Biochemical evidence for pulmonary endothelial cell injury after carbon tetrachloride administration in mice. J Pharmacol Exp Ther 222: 641–644.

40. Badil P, Kristovà V, Cernà A, Janega P, Pechañovà O, et al. (2006) Red wine polyphenols prevent endothelial damage induced by CCl4 administration. Physiol Res 55: 245–251.

41. Reden M. (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335–340.

42. García-Compeán D, Jaquez-Quintana JO, González-González JA, Maldonado- Garza H (2009) Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 15: 280–288.